Human Beta-Defensin 2
Evidence: CAntimicrobial / Innate-Defense Peptides
Evidence Snapshot
What this grade covers
Composite proposed grade: identity/expression B; direct antimicrobial activity (discovery-era, organism-general) C; salt-sensitivity limitation B; anti-biofilm activity C; CCR6/chemotactic context B (receptor-context only, not efficacy); genomic/paralog disease-association context C.
Regulatory Context
Endogenous human peptide; no native hBD-2 drug product approval record identified in this review.
Research Takeaway
Human beta-defensin 2 (hBD-2) is a ~41-residue, three-disulfide-bond peptide encoded by DEFB4A, originally isolated from psoriatic skin scale.
Evidence boundary: DEFB4A/DEFB4B paralog-provenance ambiguity exists at the genomic level; this identity claim does not resolve which paralog copy any given protein sample derives from.
See all 5 evidence claims →Quick Summary
Human beta-defensin 2 (hBD-2) is an inducible human epithelial antimicrobial peptide, first isolated from psoriatic skin. Its antibacterial activity is salt-sensitive -- markedly reduced at physiological airway salt concentrations -- and it has a separate anti-biofilm mechanism against Pseudomonas aeruginosa distinct from direct killing, plus a chemotactic signaling role via the receptor CCR6 that is separate from its antimicrobial function.
Mechanism & Research Overview
Human beta-defensin 2 (hBD-2) is an inducible human epithelial antimicrobial peptide, first isolated from psoriatic skin. Its antibacterial activity is salt-sensitive -- markedly reduced at physiological airway salt concentrations -- and it has a separate anti-biofilm mechanism against Pseudomonas aeruginosa distinct from direct killing, plus a chemotactic signaling role via the receptor CCR6 that is separate from its antimicrobial function.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
Human beta-defensin 2 (hBD-2) is a ~41-residue, three-disulfide-bond peptide encoded by DEFB4A, originally isolated from psoriatic skin scale.
Does not establish
Evidence boundary: DEFB4A/DEFB4B paralog-provenance ambiguity exists at the genomic level; this identity claim does not resolve which paralog copy any given protein sample derives from.
Sources: A peptide antibiotic from human skin
Supported
hBD-2 is expressed in human lung airway epithelium and shows antibacterial activity that is markedly reduced (salt-sensitive) at physiological airway salt concentrations, acting synergistically with lysozyme and lactoferrin.
Does not establish
Evidence boundary: Salt-sensitivity is a genuine functional limitation, not a footnote -- must not be presented as full potency at physiological salt concentrations.
Sources: Human beta-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung
Supported
At nanomolar concentrations, hBD-2 significantly reduces Pseudomonas aeruginosa biofilm formation without compromising bacterial metabolic activity.
Does not establish
Evidence boundary: Single source. This anti-biofilm mechanism is DISTINCT from direct bactericidal killing and must not be conflated with it.
Supported
hBD-2 is chemotactic for immature dendritic cells and memory T cells via the chemokine receptor CCR6, a mechanism proposed to link innate and adaptive immunity.
Does not establish
Evidence boundary: This is a signaling/chemotaxis finding, NOT an antimicrobial-efficacy finding, and is SHARED with hBD-3 -- must not imply the two peptides have equivalent antimicrobial efficacy on this basis.
Sources: Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6
Supported
Increased genomic copy number at the beta-defensin gene cluster (including DEFB4A) is associated with psoriasis risk in human genetic studies.
Does not establish
Evidence boundary: This is a genomic-association finding, not a protein-activity or efficacy finding -- hBD-2 protein levels were not directly measured in this study.
Sources: Psoriasis is associated with increased beta-defensin genomic copy number
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
hBD-2's antibacterial activity is substantially reduced at salt concentrations similar to human airway fluid compared to lower-salt lab conditions -- a genuine limitation.Safety Consideration
The psoriasis association is a genomic copy-number finding, correlative, not a demonstrated protein-activity causal mechanism.Safety Consideration
The anti-biofilm mechanism against P. aeruginosa is mechanistically distinct from direct bactericidal killing and must not be conflated with it.
Research Areas Being Studied
Research areas discussed on this page reflect the Antimicrobial / Innate-Defense Peptides category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
- Altered serum levels of human neutrophil peptides (HNP) and human beta-defensin 2 (hBD2) in Wegener's granulomatosis (2011):
- Elevated levels of human beta-defensin 2 and human neutrophil peptides in systemic lupus erythematosus (2010):
- Psoriasis is associated with increased beta-defensin genomic copy number (2008):
- Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6 (1999):
- Human beta-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung (1998):
- A peptide antibiotic from human skin (1997):
Study Tables by Evidence Type
Human Studies & Clinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Altered serum levels of human neutrophil peptides (HNP) and human beta-defensin 2 (hBD2) in Wegener's granulomatosis | 2011 | 17 Wegener's granulomatosis (ANCA-associated vasculitis) patients, 24 matched healthy controls | Wegener's granulomatosis patients showed higher serum levels of hBD2 and pooled HNP than controls. | ||
| Elevated levels of human beta-defensin 2 and human neutrophil peptides in systemic lupus erythematosus | 2010 | systemic lupus erythematosus patients vs. controls | Elevated levels of hBD2 and pooled human neutrophil peptides (HNP) were observed in SLE patients. | ||
| Psoriasis is associated with increased beta-defensin genomic copy number | 2008 | human genetic-association cohorts (Dutch and German psoriasis patients/controls) | Increased genomic copy number at the beta-defensin gene cluster (including DEFB4A) is associated with psoriasis risk. | ||
| Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6 | 1999 | human/transfected cell lines (CCR6) | Human beta-defensins are chemotactic for immature dendritic cells and memory T cells via CCR6. | ||
| Human beta-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung | 1998 | human lung airway epithelium | hBD-2 is expressed in human lung airway epithelium; its antibacterial activity is salt-sensitive, markedly reduced at physiological airway salt concentrations, and synergistic with lysozyme and lactoferrin. | ||
| A peptide antibiotic from human skin | 1997 | human psoriatic skin scale | Original isolation of hBD-2 from psoriatic skin, showing broad antibacterial activity against multiple organisms as tested. |
Animal / Cell / Preclinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| The Antimicrobial Peptide Human Beta-Defensin 2 Inhibits Biofilm Production of Pseudomonas aeruginosa Without Compromising Metabolic Activity | 2020 | in vitro Pseudomonas aeruginosa assay | At nanomolar concentrations, hBD-2 significantly reduces Pseudomonas aeruginosa biofilm formation without compromising bacterial metabolic activity. |
Regulatory Documents & Official Trial Registries
No Regulatory Documents & Official Trial Registries Listed Yet
This section will be updated as sources are added.
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Educational information only. This page summarizes published research on endogenous human beta-defensin 2 and does not constitute medical advice, a treatment recommendation, or dosing guidance for any related substance.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Published. Last updated 2026-08-29.
Follow research updates for Human Beta-Defensin 2
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.